JPRN-jRCT2080220193未知2 期
A phase II study of ixabepilone (BMS-247550) in patients with metastatic breast cancer previously treated with an Anthracycline and who are Taxane resistant
Bristol-Myers K.K.0 个研究点目标入组 54 人开始时间: 2005年12月21日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 54
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- Female
入选标准
- •1. Diagnosis of histologically-confirmed, metastatic or advanced breast cancer. 2. Presence of at least one unidimensionally measurable disease. 3. No more than three prior chemotherapy regimens for metastatic disease. 4. Patients with metastatic breast cancer previously treated with an Anthracycline and who are resistant to Taxane. 5. Performance status 0 - 1.
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
Randomized Phase II study of Ixabepilone Plus Trastuzumab vs. Docetaxel Plus Trastuzumab in Female Subjects with Her2+ Locally Advanced and/or Metastatic Breast Cancer - NDEUCTR2007-000721-21-ITBristol-Myers Squibb International Corporation80
进行中（未招募）
1 期
Randomized Phase II study of Ixabepilone Plus Trastuzumab vs. Docetaxel Plus Trastuzumab in Female Subjects with Her2+ Locally Advanced and/or Metastatic Breast Cancer.Estudio fase II de Ixabepilona y Trastuzumab versus Docetaxel y Trastuzumab en mujeres con cáncer de mama localmente avanzado y/o mestatásico con sobresexpresión de Her2.Female Subjects with Her2+ Locally Advanced and/or Metastatic Breast CancerMujeres con cáncer de mama localmente avanzado y/o mestatásico con sobreexpresión de Her2.MedDRA version: 9.1Level: LLTClassification code 10065430Term: HER-2 positive breast cancerEUCTR2007-000721-21-ESBristol-Myers Squibb International Corporation80
进行中（未招募）
不适用
A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Subjects With Advanced Non-Small Cell Lung Cancer. - NDAdvanced non-small cell lung cancer.MedDRA version: 9.1Level: LLTClassification code 10029514Term: Non-small cell lung cancer NOSEUCTR2008-000977-39-ITBristol-Myers Squibb International Corporation105
进行中（未招募）
1 期
A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Subjects With Advanced Non-Small Cell Lung Cancer / Estudio fase II aleatorizado de ixabepilona mas carboplatino y paclitaxel mas carboplatino en sujetos con cancer de pulmon no microcitico avanzado+ Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (version 1.0, dated 19-Mar-08) / Enmienda sobre muestras de sangre para farmacogenética - Número 01 - Específica de centroAdvanced Non-Small Cell Lung Cancer / Cancer de pulmon no microcitico avanzadoMedDRA version: 9.1Level: LLTClassification code 10029514Term: Non-small cell lung cancer NOSEUCTR2008-000977-39-ESBristol-Myers Squibb International Corporation320
进行中（未招募）
不适用
A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Subjects With Advanced Non-Small Cell Lung CancerRevised Protocol 02 incorporating Amendment 03 (version 4.0 dated 01-Sep-09)+ Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (version 1.0, dated 19-Mar-08)Advanced Non-Small Cell Lung CancerMedDRA version: 9.1Level: LLTClassification code 10029514Term: Non-small cell lung cancer NOSEUCTR2008-000977-39-DEBristol-Myers Squibb International Corporation320